Global Human Papillomavirus (HPV) Vaccines Market - 2025-2033
Global Human Papillomavirus (HPV) Vaccines Market – Industry Trends & Outlook
The global human papillomavirus (HPV) vaccine market size reached US$ 3,043.19 Million in 2024 and is expected to reach US$ 12,361.15 Million by 2033, growing at a CAGR of 16.9% during the forecast period 2025-2033.
HPV vaccines protect against infection with human papillomaviruses (HPV), a group of over 200 related viruses, more than 40 of which are transmitted through direct sexual contact. Among these, two types are responsible for genital warts, while about a dozen high-risk types can lead to cancers such as cervical, anal, oropharyngeal, penile, vulvar, and vaginal cancers.
Key drivers fueling market growth are the rising burden of HPV-related cancers, strong governmental and international support for vaccination, improved vaccine accessibility, and growing investments from pharmaceutical companies. Opportunities abound in emerging markets, the introduction of new vaccine formulations, and integration with broader adolescent health initiatives.
The scope of the market encompasses bivalent, tetravalent, and nonavalent vaccines, targeting prevention of cervical, anal, vulvar, vaginal, penile, and oropharyngeal cancers. North America continues to dominate the market, holding nearly half of the global share, while the Asia-Pacific region is poised for the fastest growth due to rising HPV-related cancer incidence and expanding immunization programs.
Industry outlook is optimistic, driven by increasing disease awareness, government initiatives, and global health partnerships. Trends shaping the market include innovation in adjuvant technology, expanded focus on immunocompromised and LGBTQ+ populations, integration of vaccination with cancer screening, and the rise of community-based education programs.
Market insights highlight the rapid scale-up of both supply and demand, particularly in underserved regions, and the central role of HPV vaccination in comprehensive cancer control strategies. Industry reports consistently emphasize the importance of health equity, vaccine equity, and market-shaping efforts by organizations like Gavi, UNICEF, and WHO to improve supply, pricing, and access globally. Overall, the HPV vaccines market is set for sustained, impactful growth, underpinned by innovation, policy support, and a global commitment to reducing HPV-related disease burden.
Global Human Papillomavirus (HPV) Vaccines Market Dynamics: Drivers & Restraints
Rising Prevalence of Cervical Cancer
The rising prevalence of cervical cancer-now the fourth most common cancer in women globally, as per World Health Organization (WHO) data in March 2024, with around 660,000 new cases and 350,000 deaths in 2022-is a powerful driver for growth in the global human papillomavirus (HPV) vaccines market. This burden is especially acute in low- and middle-income countries (LMICs), which account for about 94% of cervical cancer deaths, and in regions such as sub-Saharan Africa, Central America, and South-East Asia, where incidence and mortality rates are highest.
The high incidence and mortality rates of cervical cancer, particularly in LMICs, have heightened awareness among governments, health organizations, and the public about the need for effective prevention. This has led to greater prioritization of HPV vaccination as a public health strategy. Countries with the highest cervical cancer rates-such as those in sub-Saharan Africa and South-East Asia-are increasingly introducing or scaling up HPV vaccination programs. As more LMICs add HPV vaccines to their national immunization schedules, the market for these vaccines continues to expand.
Accessibility and Supply Chain Issues
Accessibility and supply chain challenges have been persistent restraints in the global human papillomavirus (HPV) vaccines market, particularly impacting low- and middle-income countries (LMICs) where the burden of HPV-related diseases is highest.
Rapid increases in demand, driven by expanded vaccination programs, have outpaced manufacturers’ ability to scale up production, presenting extraordinary challenges for timely supply. Technology transfers to expand global manufacturing capacity have been limited, and the process of bringing new suppliers to market with WHO-prequalified products is slow.
Accessibility and supply chain issues have significantly limited the reach and impact of HPV vaccination programs worldwide. Addressing these barriers through increased manufacturing capacity, diversified suppliers, improved logistics, and sustained funding remains critical for achieving global cervical cancer prevention goals.
Global Human Papillomavirus (HPV) Vaccines Market - Segment Analysis
The global human papillomavirus (HPV) vaccine market is segmented based on type, gender, age group, indication, and region.
Indication:
The cervical cancer segment was valued at US$ 1,668.33 million in 2024 and is estimated to reach US$ 6,469.87 million by 2033, growing at a CAGR of 14.4% during the forecast period from 2025-2033
Human papillomavirus (HPV) is a highly prevalent sexually transmitted virus, infecting over 80% of individuals by age 45. While most HPV infections are asymptomatic, the virus is responsible for a range of cancers, most notably the majority of cervical cancer. As per World Health Organization (WHO) data in 2022, there were an estimated 661,000 new cases of cervical cancer and more than 348,000 related deaths worldwide, making it the fourth leading cause of both cancer incidence and mortality among women. More than 90% of cervical cancer deaths occur in low- and middle-income countries, highlighting significant global health disparities.
This segment is the primary focus of national immunization programs and global health initiatives such as those led by the World Health Organization (WHO), GAVI, and UNICEF, which prioritize vaccination of adolescent girls to prevent cervical cancer.
The high disease burden, especially in low- and middle-income countries (LMICs) where regular screening is limited, further intensifies the demand for prophylactic HPV vaccines. Additionally, increasing awareness, inclusion of HPV vaccines in school-based immunization programs, and the growing availability of low-cost domestic vaccines from manufacturers in India and China have accelerated market penetration.
Technological advancements and the introduction of nonavalent vaccines with broader strain coverage have also contributed to improved protection against cervical cancer and its associated precancerous lesions, strengthening the growth trajectory of this segment globally.
Global Human Papillomavirus (HPV) Vaccines Market - Geographical Analysis
The North America human papillomavirus (HPV) vaccine market was valued at US$ 1,143.64 million in 2024 and is estimated to reach US$ 4,819.32 million by 2033, growing at a CAGR of 15.3% during the forecast period from 2025-2033
The North America human papillomavirus (HPV) vaccines market is driven by several key factors that collectively support its growth and leadership in the global landscape. A primary driver is the high burden of HPV-related cancers, including cervical, anal, and oropharyngeal cancers, which has heightened the urgency for preventive measures across the region.
Robust healthcare infrastructure and widespread access to medical services enable early screening and efficient vaccine delivery, while strong governmental and public health initiatives-such as school-based vaccination programs and awareness campaigns-have significantly increased vaccine uptake.
Additionally, frequent product launches, regulatory approvals, and expanded indications by leading market players-such as the approval of Gardasil 9 for broader age groups-promote market expansion and accessibility.
Investments in research and development, a favorable regulatory environment, and strategic collaborations between public and private sectors also contribute to the market’s growth and resilience. Collectively, these drivers ensure that North America remains at the forefront of HPV vaccine adoption and innovation, supporting ongoing efforts to reduce the incidence and mortality of HPV-related diseases.
The Asia-Pacific human papillomavirus (HPV) vaccine market was valued at US$ 605.23 million in 2024 and is estimated to reach US$ 3,292.92 million by 2033, growing at a CAGR of 18.3% during the forecast period from 2025-2033
The Asia-Pacific HPV vaccines market is one of the fastest-growing regions globally. It includes major countries such as Japan, China, India, South Korea, Australia, and Southeast Asian nations. The market is driven by rising awareness, government initiatives, and the increasing incidence of HPV-related cancers.
The incidence of cervical and other HPV-related cancers is increasing in Asia-Pacific, especially in countries with large populations like India and China. Japan has a significant focus on cervical cancer prevention due to its public health impact.
Many governments (including Japan, Australia, and China) have launched or expanded national immunization programs for HPV vaccination. Subsidies and school-based vaccination campaigns are boosting coverage.
Japan is a major market in the region. After a period of suspended recommendations, the government resumed proactive HPV vaccination in 2022, leading to a surge in vaccination rates. Japan’s robust healthcare infrastructure and public health policies are expected to further drive market growth.
Global Human Papillomavirus (HPV) Vaccines Market - Competitive Landscape (Major Players)
Top companies in the human papillomavirus (HPV) vaccine market include Merck & Co., Inc., GSK plc, Wantai BioPharm., Walvax Biotechnology Co., Ltd., Serum Institute of India Pvt. Ltd., and Jiangsu Recbio Technology Co., Ltd., among others.
Global Human Papillomavirus (HPV) Vaccines Market - Competitive Landscape (Emerging Players)
Emerging companies in the human papillomavirus (HPV) vaccine market include DCVMN International, Shanghai Zerun Biotech Co., Ltd., Shanghai Bovax Biotechnology Co., Ltd., Jiangsu Recbio Technology Co., Ltd., Toragen, BlueSky Immunotherapies, Antiva Biosciences, Precigen, INOVIO Pharmaceuticals, and BioNTech SE, among others.
The global human papillomavirus (HPV) vaccine market size reached US$ 3,043.19 Million in 2024 and is expected to reach US$ 12,361.15 Million by 2033, growing at a CAGR of 16.9% during the forecast period 2025-2033.
HPV vaccines protect against infection with human papillomaviruses (HPV), a group of over 200 related viruses, more than 40 of which are transmitted through direct sexual contact. Among these, two types are responsible for genital warts, while about a dozen high-risk types can lead to cancers such as cervical, anal, oropharyngeal, penile, vulvar, and vaginal cancers.
Key drivers fueling market growth are the rising burden of HPV-related cancers, strong governmental and international support for vaccination, improved vaccine accessibility, and growing investments from pharmaceutical companies. Opportunities abound in emerging markets, the introduction of new vaccine formulations, and integration with broader adolescent health initiatives.
The scope of the market encompasses bivalent, tetravalent, and nonavalent vaccines, targeting prevention of cervical, anal, vulvar, vaginal, penile, and oropharyngeal cancers. North America continues to dominate the market, holding nearly half of the global share, while the Asia-Pacific region is poised for the fastest growth due to rising HPV-related cancer incidence and expanding immunization programs.
Industry outlook is optimistic, driven by increasing disease awareness, government initiatives, and global health partnerships. Trends shaping the market include innovation in adjuvant technology, expanded focus on immunocompromised and LGBTQ+ populations, integration of vaccination with cancer screening, and the rise of community-based education programs.
Market insights highlight the rapid scale-up of both supply and demand, particularly in underserved regions, and the central role of HPV vaccination in comprehensive cancer control strategies. Industry reports consistently emphasize the importance of health equity, vaccine equity, and market-shaping efforts by organizations like Gavi, UNICEF, and WHO to improve supply, pricing, and access globally. Overall, the HPV vaccines market is set for sustained, impactful growth, underpinned by innovation, policy support, and a global commitment to reducing HPV-related disease burden.
Global Human Papillomavirus (HPV) Vaccines Market Dynamics: Drivers & Restraints
Rising Prevalence of Cervical Cancer
The rising prevalence of cervical cancer-now the fourth most common cancer in women globally, as per World Health Organization (WHO) data in March 2024, with around 660,000 new cases and 350,000 deaths in 2022-is a powerful driver for growth in the global human papillomavirus (HPV) vaccines market. This burden is especially acute in low- and middle-income countries (LMICs), which account for about 94% of cervical cancer deaths, and in regions such as sub-Saharan Africa, Central America, and South-East Asia, where incidence and mortality rates are highest.
The high incidence and mortality rates of cervical cancer, particularly in LMICs, have heightened awareness among governments, health organizations, and the public about the need for effective prevention. This has led to greater prioritization of HPV vaccination as a public health strategy. Countries with the highest cervical cancer rates-such as those in sub-Saharan Africa and South-East Asia-are increasingly introducing or scaling up HPV vaccination programs. As more LMICs add HPV vaccines to their national immunization schedules, the market for these vaccines continues to expand.
Accessibility and Supply Chain Issues
Accessibility and supply chain challenges have been persistent restraints in the global human papillomavirus (HPV) vaccines market, particularly impacting low- and middle-income countries (LMICs) where the burden of HPV-related diseases is highest.
Rapid increases in demand, driven by expanded vaccination programs, have outpaced manufacturers’ ability to scale up production, presenting extraordinary challenges for timely supply. Technology transfers to expand global manufacturing capacity have been limited, and the process of bringing new suppliers to market with WHO-prequalified products is slow.
Accessibility and supply chain issues have significantly limited the reach and impact of HPV vaccination programs worldwide. Addressing these barriers through increased manufacturing capacity, diversified suppliers, improved logistics, and sustained funding remains critical for achieving global cervical cancer prevention goals.
Global Human Papillomavirus (HPV) Vaccines Market - Segment Analysis
The global human papillomavirus (HPV) vaccine market is segmented based on type, gender, age group, indication, and region.
Indication:
The cervical cancer segment was valued at US$ 1,668.33 million in 2024 and is estimated to reach US$ 6,469.87 million by 2033, growing at a CAGR of 14.4% during the forecast period from 2025-2033
Human papillomavirus (HPV) is a highly prevalent sexually transmitted virus, infecting over 80% of individuals by age 45. While most HPV infections are asymptomatic, the virus is responsible for a range of cancers, most notably the majority of cervical cancer. As per World Health Organization (WHO) data in 2022, there were an estimated 661,000 new cases of cervical cancer and more than 348,000 related deaths worldwide, making it the fourth leading cause of both cancer incidence and mortality among women. More than 90% of cervical cancer deaths occur in low- and middle-income countries, highlighting significant global health disparities.
This segment is the primary focus of national immunization programs and global health initiatives such as those led by the World Health Organization (WHO), GAVI, and UNICEF, which prioritize vaccination of adolescent girls to prevent cervical cancer.
The high disease burden, especially in low- and middle-income countries (LMICs) where regular screening is limited, further intensifies the demand for prophylactic HPV vaccines. Additionally, increasing awareness, inclusion of HPV vaccines in school-based immunization programs, and the growing availability of low-cost domestic vaccines from manufacturers in India and China have accelerated market penetration.
Technological advancements and the introduction of nonavalent vaccines with broader strain coverage have also contributed to improved protection against cervical cancer and its associated precancerous lesions, strengthening the growth trajectory of this segment globally.
Global Human Papillomavirus (HPV) Vaccines Market - Geographical Analysis
The North America human papillomavirus (HPV) vaccine market was valued at US$ 1,143.64 million in 2024 and is estimated to reach US$ 4,819.32 million by 2033, growing at a CAGR of 15.3% during the forecast period from 2025-2033
The North America human papillomavirus (HPV) vaccines market is driven by several key factors that collectively support its growth and leadership in the global landscape. A primary driver is the high burden of HPV-related cancers, including cervical, anal, and oropharyngeal cancers, which has heightened the urgency for preventive measures across the region.
Robust healthcare infrastructure and widespread access to medical services enable early screening and efficient vaccine delivery, while strong governmental and public health initiatives-such as school-based vaccination programs and awareness campaigns-have significantly increased vaccine uptake.
Additionally, frequent product launches, regulatory approvals, and expanded indications by leading market players-such as the approval of Gardasil 9 for broader age groups-promote market expansion and accessibility.
Investments in research and development, a favorable regulatory environment, and strategic collaborations between public and private sectors also contribute to the market’s growth and resilience. Collectively, these drivers ensure that North America remains at the forefront of HPV vaccine adoption and innovation, supporting ongoing efforts to reduce the incidence and mortality of HPV-related diseases.
The Asia-Pacific human papillomavirus (HPV) vaccine market was valued at US$ 605.23 million in 2024 and is estimated to reach US$ 3,292.92 million by 2033, growing at a CAGR of 18.3% during the forecast period from 2025-2033
The Asia-Pacific HPV vaccines market is one of the fastest-growing regions globally. It includes major countries such as Japan, China, India, South Korea, Australia, and Southeast Asian nations. The market is driven by rising awareness, government initiatives, and the increasing incidence of HPV-related cancers.
The incidence of cervical and other HPV-related cancers is increasing in Asia-Pacific, especially in countries with large populations like India and China. Japan has a significant focus on cervical cancer prevention due to its public health impact.
Many governments (including Japan, Australia, and China) have launched or expanded national immunization programs for HPV vaccination. Subsidies and school-based vaccination campaigns are boosting coverage.
Japan is a major market in the region. After a period of suspended recommendations, the government resumed proactive HPV vaccination in 2022, leading to a surge in vaccination rates. Japan’s robust healthcare infrastructure and public health policies are expected to further drive market growth.
Global Human Papillomavirus (HPV) Vaccines Market - Competitive Landscape (Major Players)
Top companies in the human papillomavirus (HPV) vaccine market include Merck & Co., Inc., GSK plc, Wantai BioPharm., Walvax Biotechnology Co., Ltd., Serum Institute of India Pvt. Ltd., and Jiangsu Recbio Technology Co., Ltd., among others.
Global Human Papillomavirus (HPV) Vaccines Market - Competitive Landscape (Emerging Players)
Emerging companies in the human papillomavirus (HPV) vaccine market include DCVMN International, Shanghai Zerun Biotech Co., Ltd., Shanghai Bovax Biotechnology Co., Ltd., Jiangsu Recbio Technology Co., Ltd., Toragen, BlueSky Immunotherapies, Antiva Biosciences, Precigen, INOVIO Pharmaceuticals, and BioNTech SE, among others.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Type
2.4. Snippet by Gender
2.5. Snippet by Age Group
2.6. Snippet by Indication
2.7. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Prevalence of Cervical Cancer
3.1.1.2. Rising Vaccination Drives Against HPV
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. Accessibility and Supply Chain Issues
3.1.2.2. High Vaccine Cost and Affordability
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Development of Advanced Vaccine Formulations
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. Latin America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Pipeline Analysis
4.9. Epidemiology Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders
5. HUMAN PAPILLOMAVIRUS (HPV) VACCINES MARKET, BY TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
5.1.2. Market Attractiveness Index, By Type
5.2. Bivalent*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Quadrivalent
5.4. Nona valent
6. HUMAN PAPILLOMAVIRUS (HPV) VACCINES MARKET, BY GENDER
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
6.1.2. Market Attractiveness Index, By Gender
6.2. Female*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Male
7. HUMAN PAPILLOMAVIRUS (HPV) VACCINES MARKET, BY AGE GROUP
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
7.1.2. Market Attractiveness Index, By Age Group
7.2. Children*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Adults
8. HUMAN PAPILLOMAVIRUS (HPV) VACCINES MARKET, BY INDICATION
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.1.2. Market Attractiveness Index, By Indication
8.2. Cervical Cancer*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Vaginal Cancer
8.4. Anal Cancer
8.5. Others
9. HUMAN PAPILLOMAVIRUS (HPV) VACCINES MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.7.1. U.S.
9.2.7.2. Canada
9.2.7.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.7.1. Germany
9.3.7.2. UK
9.3.7.3. France
9.3.7.4. Spain
9.3.7.5. Italy
9.3.7.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.7.1. China
9.4.7.2. India
9.4.7.3. Japan
9.4.7.4. South Korea
9.4.7.5. Rest of Asia-Pacific
9.5. South America
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.7.1. Brazil
9.5.7.2. Argentina
9.5.7.3. Rest of South America
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
10.1. Competitive Overview and Key Market Players
10.2. Market Share Analysis and Positioning Matrix
10.3. Strategic Partnerships, Mergers & Acquisitions
10.4. Key Developments in Product Portfolios and Innovations
10.5. Company Benchmarking
11. COMPANY PROFILES
Major Players
11.1. Merck & Co., Inc.
11.1.1. Company Overview
11.1.2. Product Portfolio
11.1.2.1. Product Description
11.1.2.2. Product Key Performance Indicators (KPIs)
11.1.2.3. Historic and Forecasted Product Sales
11.1.2.4. Product Sales Volume
11.1.3. Financial Overview
11.1.3.1. Company Revenue
11.1.3.2. Geographical Revenue Shares
11.1.3.3. Revenue Forecasts
11.1.4. Key Developments
11.1.4.1. Mergers & Acquisitions
11.1.4.2. Key Product Development Activities
11.1.4.3. Regulatory Approvals, etc.
11.1.5. SWOT Analysis
11.2. GSK plc.
11.3. Wantai BioPharm.
11.4. Walvax Biotechnology Co., Ltd.
11.5. Serum Institute of India Pvt. Ltd.
Emerging Players
11.6. DCVMN International.
11.7. Shanghai Zerun Biotech Co., Ltd.
11.8. Shanghai Bovax Biotechnology Co., Ltd.
11.9. Jiangsu Recbio Technology Co., Ltd.
11.10. Toragen
11.11. BlueSky Immunotherapies
11.12. Antiva Biosciences
11.13. Precigen
11.14. INOVIO Pharmaceuticals
11.15. BioNTech SE
LIST NOT EXHAUSTIVE
12. ASSUMPTIONS AND RESEARCH METHODOLOGY
12.1. Data Collection Methods
12.2. Data Triangulation
12.3. Forecasting Techniques
12.4. Data Verification and Validation
13. APPENDIX
13.1. About Us and Services
13.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Type
2.4. Snippet by Gender
2.5. Snippet by Age Group
2.6. Snippet by Indication
2.7. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Prevalence of Cervical Cancer
3.1.1.2. Rising Vaccination Drives Against HPV
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. Accessibility and Supply Chain Issues
3.1.2.2. High Vaccine Cost and Affordability
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Development of Advanced Vaccine Formulations
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. Latin America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Pipeline Analysis
4.9. Epidemiology Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders
5. HUMAN PAPILLOMAVIRUS (HPV) VACCINES MARKET, BY TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
5.1.2. Market Attractiveness Index, By Type
5.2. Bivalent*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Quadrivalent
5.4. Nona valent
6. HUMAN PAPILLOMAVIRUS (HPV) VACCINES MARKET, BY GENDER
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
6.1.2. Market Attractiveness Index, By Gender
6.2. Female*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Male
7. HUMAN PAPILLOMAVIRUS (HPV) VACCINES MARKET, BY AGE GROUP
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
7.1.2. Market Attractiveness Index, By Age Group
7.2. Children*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Adults
8. HUMAN PAPILLOMAVIRUS (HPV) VACCINES MARKET, BY INDICATION
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.1.2. Market Attractiveness Index, By Indication
8.2. Cervical Cancer*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Vaginal Cancer
8.4. Anal Cancer
8.5. Others
9. HUMAN PAPILLOMAVIRUS (HPV) VACCINES MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.7.1. U.S.
9.2.7.2. Canada
9.2.7.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.7.1. Germany
9.3.7.2. UK
9.3.7.3. France
9.3.7.4. Spain
9.3.7.5. Italy
9.3.7.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.7.1. China
9.4.7.2. India
9.4.7.3. Japan
9.4.7.4. South Korea
9.4.7.5. Rest of Asia-Pacific
9.5. South America
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.7.1. Brazil
9.5.7.2. Argentina
9.5.7.3. Rest of South America
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
10.1. Competitive Overview and Key Market Players
10.2. Market Share Analysis and Positioning Matrix
10.3. Strategic Partnerships, Mergers & Acquisitions
10.4. Key Developments in Product Portfolios and Innovations
10.5. Company Benchmarking
11. COMPANY PROFILES
Major Players
11.1. Merck & Co., Inc.
11.1.1. Company Overview
11.1.2. Product Portfolio
11.1.2.1. Product Description
11.1.2.2. Product Key Performance Indicators (KPIs)
11.1.2.3. Historic and Forecasted Product Sales
11.1.2.4. Product Sales Volume
11.1.3. Financial Overview
11.1.3.1. Company Revenue
11.1.3.2. Geographical Revenue Shares
11.1.3.3. Revenue Forecasts
11.1.4. Key Developments
11.1.4.1. Mergers & Acquisitions
11.1.4.2. Key Product Development Activities
11.1.4.3. Regulatory Approvals, etc.
11.1.5. SWOT Analysis
11.2. GSK plc.
11.3. Wantai BioPharm.
11.4. Walvax Biotechnology Co., Ltd.
11.5. Serum Institute of India Pvt. Ltd.
Emerging Players
11.6. DCVMN International.
11.7. Shanghai Zerun Biotech Co., Ltd.
11.8. Shanghai Bovax Biotechnology Co., Ltd.
11.9. Jiangsu Recbio Technology Co., Ltd.
11.10. Toragen
11.11. BlueSky Immunotherapies
11.12. Antiva Biosciences
11.13. Precigen
11.14. INOVIO Pharmaceuticals
11.15. BioNTech SE
LIST NOT EXHAUSTIVE
12. ASSUMPTIONS AND RESEARCH METHODOLOGY
12.1. Data Collection Methods
12.2. Data Triangulation
12.3. Forecasting Techniques
12.4. Data Verification and Validation
13. APPENDIX
13.1. About Us and Services
13.2. Contact Us
LIST OF TABLES
Table 1 Global Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2025, 2029 & 2033 (US$ Million)
Table 2 Global Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2025, 2029 & 2033 (US$ Million)
Table 3 Global Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2025, 2029 & 2033 (US$ Million)
Table 4 Global Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2025, 2029 & 2033 (US$ Million)
Table 5 Global Human Papillomavirus (HPV) Vaccines Market Value, By Region, 2025, 2029 & 2033 (US$ Million)
Table 6 Global Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2025, 2029 & 2033 (US$ Million)
Table 7 Global Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2022-2033 (US$ Million)
Table 8 Global Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2025, 2029 & 2033 (US$ Million)
Table 9 Global Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2022-2033 (US$ Million)
Table 10 Global Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2025, 2029 & 2033 (US$ Million)
Table 11 Global Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2022-2033 (US$ Million)
Table 12 Global Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2025, 2029 & 2033 (US$ Million)
Table 13 Global Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2022-2033 (US$ Million)
Table 14 Global Human Papillomavirus (HPV) Vaccines Market Value, By Region, 2025, 2029 & 2033 (US$ Million)
Table 15 Global Human Papillomavirus (HPV) Vaccines Market Value, By Region, 2022-2033 (US$ Million)
Table 16 North America Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2022-2033 (US$ Million)
Table 17 North America Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2022-2033 (US$ Million)
Table 18 North America Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2022-2033 (US$ Million)
Table 19 North America Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2022-2033 (US$ Million)
Table 20 North America Human Papillomavirus (HPV) Vaccines Market Value, By Country, 2022-2033 (US$ Million)
Table 21 South America Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2022-2033 (US$ Million)
Table 22 South America Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2022-2033 (US$ Million)
Table 23 South America Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2022-2033 (US$ Million)
Table 24 South America Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2022-2033 (US$ Million)
Table 25 South America Human Papillomavirus (HPV) Vaccines Market Value, By Country, 2022-2033 (US$ Million)
Table 26 Europe Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2022-2033 (US$ Million)
Table 27 Europe Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2022-2033 (US$ Million)
Table 28 Europe Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2022-2033 (US$ Million)
Table 29 Europe Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2022-2033 (US$ Million)
Table 30 Europe Human Papillomavirus (HPV) Vaccines Market Value, By Country, 2022-2033 (US$ Million)
Table 31 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2022-2033 (US$ Million)
Table 32 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2022-2033 (US$ Million)
Table 33 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2022-2033 (US$ Million)
Table 34 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2022-2033 (US$ Million)
Table 35 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Value, By Country, 2022-2033 (US$ Million)
Table 36 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2022-2033 (US$ Million)
Table 37 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2022-2033 (US$ Million)
Table 38 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2022-2033 (US$ Million)
Table 39 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2022-2033 (US$ Million)
Table 40 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Value, By Country, 2022-2033 (US$ Million)
Table 41 Merck & Co., Inc.: Overview
Table 42 Merck & Co., Inc.: Product Portfolio
Table 43 Merck & Co., Inc.: Key Developments
Table 44 GSK plc.: Overview
Table 45 GSK plc.: Product Portfolio
Table 46 GSK plc: Key Developments
Table 47 Wantai BioPharm.: Overview
Table 48 Wantai BioPharm.: Product Portfolio
Table 49 Wantai BioPharm.: Key Developments
Table 50 Walvax Biotechnology Co., Ltd.: Overview
Table 51 Walvax Biotechnology Co., Ltd.: Product Portfolio
Table 52 Walvax Biotechnology Co., Ltd.: Key Developments
Table 53 Serum Institute of India Pvt. Ltd.: Overview
Table 54 Serum Institute of India Pvt. Ltd.: Product Portfolio
Table 55 Serum Institute of India Pvt. Ltd.: Key Developments
Table 56 DCVMN International.: Overview
Table 57 DCVMN International.: Product Portfolio
Table 58 DCVMN International.: Key Developments
Table 59 Shanghai Zerun Biotech Co., Ltd.: Overview
Table 60 Shanghai Zerun Biotech Co., Ltd.: Product Portfolio
Table 61 Shanghai Zerun Biotech Co., Ltd.: Key Developments
Table 62 Shanghai Bovax Biotechnology Co., Ltd.: Overview
Table 63 Shanghai Bovax Biotechnology Co., Ltd.: Product Portfolio
Table 64 Shanghai Bovax Biotechnology Co., Ltd.: Key Developments
Table 65 Jiangsu Recbio Technology Co., Ltd.: Overview
Table 66 Jiangsu Recbio Technology Co., Ltd.: Product Portfolio
Table 67 Jiangsu Recbio Technology Co., Ltd.: Key Developments
Table 68 Toragen: Overview
Table 69 Toragen: Product Portfolio
Table 70 Toragen: Key Developments
Table 71 BlueSky Immunotherapies: Overview
Table 72 BlueSky Immunotherapies: Product Portfolio
Table 73 BlueSky Immunotherapies: Key Developments
Table 74 Antiva Biosciences: Overview
Table 75 Antiva Biosciences: Product Portfolio
Table 76 Antiva Biosciences: Key Developments
Table 77 Precigen: Overview
Table 78 Precigen: Product Portfolio
Table 79 Precigen: Key Developments
Table 80 INOVIO Pharmaceuticals: Overview
Table 81 INOVIO Pharmaceuticals: Product Portfolio
Table 82 INOVIO Pharmaceuticals: Key Developments
Table 83 BioNTech SE: Overview
Table 84 BioNTech SE: Product Portfolio
Table 85 BioNTech SE: Key Developments
Table 1 Global Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2025, 2029 & 2033 (US$ Million)
Table 2 Global Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2025, 2029 & 2033 (US$ Million)
Table 3 Global Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2025, 2029 & 2033 (US$ Million)
Table 4 Global Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2025, 2029 & 2033 (US$ Million)
Table 5 Global Human Papillomavirus (HPV) Vaccines Market Value, By Region, 2025, 2029 & 2033 (US$ Million)
Table 6 Global Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2025, 2029 & 2033 (US$ Million)
Table 7 Global Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2022-2033 (US$ Million)
Table 8 Global Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2025, 2029 & 2033 (US$ Million)
Table 9 Global Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2022-2033 (US$ Million)
Table 10 Global Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2025, 2029 & 2033 (US$ Million)
Table 11 Global Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2022-2033 (US$ Million)
Table 12 Global Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2025, 2029 & 2033 (US$ Million)
Table 13 Global Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2022-2033 (US$ Million)
Table 14 Global Human Papillomavirus (HPV) Vaccines Market Value, By Region, 2025, 2029 & 2033 (US$ Million)
Table 15 Global Human Papillomavirus (HPV) Vaccines Market Value, By Region, 2022-2033 (US$ Million)
Table 16 North America Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2022-2033 (US$ Million)
Table 17 North America Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2022-2033 (US$ Million)
Table 18 North America Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2022-2033 (US$ Million)
Table 19 North America Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2022-2033 (US$ Million)
Table 20 North America Human Papillomavirus (HPV) Vaccines Market Value, By Country, 2022-2033 (US$ Million)
Table 21 South America Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2022-2033 (US$ Million)
Table 22 South America Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2022-2033 (US$ Million)
Table 23 South America Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2022-2033 (US$ Million)
Table 24 South America Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2022-2033 (US$ Million)
Table 25 South America Human Papillomavirus (HPV) Vaccines Market Value, By Country, 2022-2033 (US$ Million)
Table 26 Europe Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2022-2033 (US$ Million)
Table 27 Europe Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2022-2033 (US$ Million)
Table 28 Europe Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2022-2033 (US$ Million)
Table 29 Europe Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2022-2033 (US$ Million)
Table 30 Europe Human Papillomavirus (HPV) Vaccines Market Value, By Country, 2022-2033 (US$ Million)
Table 31 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2022-2033 (US$ Million)
Table 32 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2022-2033 (US$ Million)
Table 33 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2022-2033 (US$ Million)
Table 34 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2022-2033 (US$ Million)
Table 35 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Value, By Country, 2022-2033 (US$ Million)
Table 36 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2022-2033 (US$ Million)
Table 37 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2022-2033 (US$ Million)
Table 38 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2022-2033 (US$ Million)
Table 39 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2022-2033 (US$ Million)
Table 40 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Value, By Country, 2022-2033 (US$ Million)
Table 41 Merck & Co., Inc.: Overview
Table 42 Merck & Co., Inc.: Product Portfolio
Table 43 Merck & Co., Inc.: Key Developments
Table 44 GSK plc.: Overview
Table 45 GSK plc.: Product Portfolio
Table 46 GSK plc: Key Developments
Table 47 Wantai BioPharm.: Overview
Table 48 Wantai BioPharm.: Product Portfolio
Table 49 Wantai BioPharm.: Key Developments
Table 50 Walvax Biotechnology Co., Ltd.: Overview
Table 51 Walvax Biotechnology Co., Ltd.: Product Portfolio
Table 52 Walvax Biotechnology Co., Ltd.: Key Developments
Table 53 Serum Institute of India Pvt. Ltd.: Overview
Table 54 Serum Institute of India Pvt. Ltd.: Product Portfolio
Table 55 Serum Institute of India Pvt. Ltd.: Key Developments
Table 56 DCVMN International.: Overview
Table 57 DCVMN International.: Product Portfolio
Table 58 DCVMN International.: Key Developments
Table 59 Shanghai Zerun Biotech Co., Ltd.: Overview
Table 60 Shanghai Zerun Biotech Co., Ltd.: Product Portfolio
Table 61 Shanghai Zerun Biotech Co., Ltd.: Key Developments
Table 62 Shanghai Bovax Biotechnology Co., Ltd.: Overview
Table 63 Shanghai Bovax Biotechnology Co., Ltd.: Product Portfolio
Table 64 Shanghai Bovax Biotechnology Co., Ltd.: Key Developments
Table 65 Jiangsu Recbio Technology Co., Ltd.: Overview
Table 66 Jiangsu Recbio Technology Co., Ltd.: Product Portfolio
Table 67 Jiangsu Recbio Technology Co., Ltd.: Key Developments
Table 68 Toragen: Overview
Table 69 Toragen: Product Portfolio
Table 70 Toragen: Key Developments
Table 71 BlueSky Immunotherapies: Overview
Table 72 BlueSky Immunotherapies: Product Portfolio
Table 73 BlueSky Immunotherapies: Key Developments
Table 74 Antiva Biosciences: Overview
Table 75 Antiva Biosciences: Product Portfolio
Table 76 Antiva Biosciences: Key Developments
Table 77 Precigen: Overview
Table 78 Precigen: Product Portfolio
Table 79 Precigen: Key Developments
Table 80 INOVIO Pharmaceuticals: Overview
Table 81 INOVIO Pharmaceuticals: Product Portfolio
Table 82 INOVIO Pharmaceuticals: Key Developments
Table 83 BioNTech SE: Overview
Table 84 BioNTech SE: Product Portfolio
Table 85 BioNTech SE: Key Developments
LIST OF FIGURES
Figure 1 Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Million)
Figure 2 Global Human Papillomavirus (HPV) Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 3 Global Human Papillomavirus (HPV) Vaccines Market Share, By Gender, 2024 & 2033 (%)
Figure 4 Global Human Papillomavirus (HPV) Vaccines Market Share, By Age Group, 2024 & 2033 (%)
Figure 5 Global Human Papillomavirus (HPV) Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 6 Global Human Papillomavirus (HPV) Vaccines Market Share, By Region, 2024 & 2033 (%)
Figure 7 Global Human Papillomavirus (HPV) Vaccines Market Y-o-Y Growth, By Type, 2023-2033 (%)
Figure 8 Fibrolamellar HCC Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Million)
Figure 9 Sarcomatoid HCC Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Million)
Figure 10 Global Human Papillomavirus (HPV) Vaccines Market Y-o-Y Growth, By Gender, 2023-2033 (%)
Figure 11 Immunotherapy Gender in Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Million)
Figure 12 Targeted therapy Gender in Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Million)
Figure 13 Radiation Therapy Gender in Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Million)
Figure 14 Surgery Gender in Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Million)
Figure 15 Ablation and Embolization Therapies Gender in Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Million)
Figure 16 Other Gender in Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Million)
Figure 17 Global Human Papillomavirus (HPV) Vaccines Market Y-o-Y Growth, By Age Group, 2023-2033 (%)
Figure 18 Global Human Papillomavirus (HPV) Vaccines Market Y-o-Y Growth, By Indication, 2023-2033 (%)
Figure 19 Global Human Papillomavirus (HPV) Vaccines Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 20 North America Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Million)
Figure 21 North America Human Papillomavirus (HPV) Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 22 North America Human Papillomavirus (HPV) Vaccines Market Share, By Gender, 2024 & 2033 (%)
Figure 23 North America Human Papillomavirus (HPV) Vaccines Market Share, By Age Group, 2024 & 2033 (%)
Figure 24 North America Human Papillomavirus (HPV) Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 25 North America Human Papillomavirus (HPV) Vaccines Market Share, By Country, 2024 & 2033 (%)
Figure 26 South America Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Million)
Figure 27 South America Human Papillomavirus (HPV) Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 28 South America Human Papillomavirus (HPV) Vaccines Market Share, By Gender, 2024 & 2033 (%)
Figure 29 South America Human Papillomavirus (HPV) Vaccines Market Share, By Age Group, 2024 & 2033 (%)
Figure 30 South America Human Papillomavirus (HPV) Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 31 South America Human Papillomavirus (HPV) Vaccines Market Share, By Country, 2024 & 2033 (%)
Figure 32 Europe Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Million)
Figure 33 Europe Human Papillomavirus (HPV) Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 34 Europe Human Papillomavirus (HPV) Vaccines Market Share, By Gender, 2024 & 2033 (%)
Figure 35 Europe Human Papillomavirus (HPV) Vaccines Market Share, By Age Group, 2024 & 2033 (%)
Figure 36 Europe Human Papillomavirus (HPV) Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 37 Europe Human Papillomavirus (HPV) Vaccines Market Share, By Country, 2024 & 2033 (%)
Figure 38 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Million)
Figure 39 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 40 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Share, By Gender, 2024 & 2033 (%)
Figure 41 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Share, By Age Group, 2024 & 2033 (%)
Figure 42 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 43 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Share, By Country, 2024 & 2033 (%)
Figure 44 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Million)
Figure 45 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 46 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Share, By Gender, 2024 & 2033 (%)
Figure 47 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Share, By Age Group, 2024 & 2033 (%)
Figure 48 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 49 Merck & Co., Inc.: Financials
Figure 50 GSK plc.: Financials
Figure 51 Wantai BioPharm.: Financials
Figure 52 Walvax Biotechnology Co., Ltd.: Financials
Figure 53 Serum Institute of India Pvt. Ltd.: Financials
Figure 54 DCVMN International.: Financials
Figure 55 Shanghai Zerun Biotech Co., Ltd.: Financials
Figure 56 Shanghai Bovax Biotechnology Co., Ltd.: Financials
Figure 57 Jiangsu Recbio Technology Co., Ltd.: Financials
Figure 58 Toragen: Financials
Figure 59 BlueSky Immunotherapies: Financials
Figure 60 Antiva Biosciences: Financials
Figure 61 Precigen: Financials
Figure 62 INOVIO Pharmaceuticals: Financials
Figure 63 BioNTech S: Financials
Figure 1 Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Million)
Figure 2 Global Human Papillomavirus (HPV) Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 3 Global Human Papillomavirus (HPV) Vaccines Market Share, By Gender, 2024 & 2033 (%)
Figure 4 Global Human Papillomavirus (HPV) Vaccines Market Share, By Age Group, 2024 & 2033 (%)
Figure 5 Global Human Papillomavirus (HPV) Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 6 Global Human Papillomavirus (HPV) Vaccines Market Share, By Region, 2024 & 2033 (%)
Figure 7 Global Human Papillomavirus (HPV) Vaccines Market Y-o-Y Growth, By Type, 2023-2033 (%)
Figure 8 Fibrolamellar HCC Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Million)
Figure 9 Sarcomatoid HCC Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Million)
Figure 10 Global Human Papillomavirus (HPV) Vaccines Market Y-o-Y Growth, By Gender, 2023-2033 (%)
Figure 11 Immunotherapy Gender in Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Million)
Figure 12 Targeted therapy Gender in Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Million)
Figure 13 Radiation Therapy Gender in Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Million)
Figure 14 Surgery Gender in Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Million)
Figure 15 Ablation and Embolization Therapies Gender in Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Million)
Figure 16 Other Gender in Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Million)
Figure 17 Global Human Papillomavirus (HPV) Vaccines Market Y-o-Y Growth, By Age Group, 2023-2033 (%)
Figure 18 Global Human Papillomavirus (HPV) Vaccines Market Y-o-Y Growth, By Indication, 2023-2033 (%)
Figure 19 Global Human Papillomavirus (HPV) Vaccines Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 20 North America Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Million)
Figure 21 North America Human Papillomavirus (HPV) Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 22 North America Human Papillomavirus (HPV) Vaccines Market Share, By Gender, 2024 & 2033 (%)
Figure 23 North America Human Papillomavirus (HPV) Vaccines Market Share, By Age Group, 2024 & 2033 (%)
Figure 24 North America Human Papillomavirus (HPV) Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 25 North America Human Papillomavirus (HPV) Vaccines Market Share, By Country, 2024 & 2033 (%)
Figure 26 South America Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Million)
Figure 27 South America Human Papillomavirus (HPV) Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 28 South America Human Papillomavirus (HPV) Vaccines Market Share, By Gender, 2024 & 2033 (%)
Figure 29 South America Human Papillomavirus (HPV) Vaccines Market Share, By Age Group, 2024 & 2033 (%)
Figure 30 South America Human Papillomavirus (HPV) Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 31 South America Human Papillomavirus (HPV) Vaccines Market Share, By Country, 2024 & 2033 (%)
Figure 32 Europe Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Million)
Figure 33 Europe Human Papillomavirus (HPV) Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 34 Europe Human Papillomavirus (HPV) Vaccines Market Share, By Gender, 2024 & 2033 (%)
Figure 35 Europe Human Papillomavirus (HPV) Vaccines Market Share, By Age Group, 2024 & 2033 (%)
Figure 36 Europe Human Papillomavirus (HPV) Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 37 Europe Human Papillomavirus (HPV) Vaccines Market Share, By Country, 2024 & 2033 (%)
Figure 38 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Million)
Figure 39 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 40 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Share, By Gender, 2024 & 2033 (%)
Figure 41 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Share, By Age Group, 2024 & 2033 (%)
Figure 42 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 43 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Share, By Country, 2024 & 2033 (%)
Figure 44 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Million)
Figure 45 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 46 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Share, By Gender, 2024 & 2033 (%)
Figure 47 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Share, By Age Group, 2024 & 2033 (%)
Figure 48 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 49 Merck & Co., Inc.: Financials
Figure 50 GSK plc.: Financials
Figure 51 Wantai BioPharm.: Financials
Figure 52 Walvax Biotechnology Co., Ltd.: Financials
Figure 53 Serum Institute of India Pvt. Ltd.: Financials
Figure 54 DCVMN International.: Financials
Figure 55 Shanghai Zerun Biotech Co., Ltd.: Financials
Figure 56 Shanghai Bovax Biotechnology Co., Ltd.: Financials
Figure 57 Jiangsu Recbio Technology Co., Ltd.: Financials
Figure 58 Toragen: Financials
Figure 59 BlueSky Immunotherapies: Financials
Figure 60 Antiva Biosciences: Financials
Figure 61 Precigen: Financials
Figure 62 INOVIO Pharmaceuticals: Financials
Figure 63 BioNTech S: Financials
